Barbituric and thiobarbituric acid derivatives have become progressively attractive to medicinal chemists due to their wide range of biological activities. Herein, different series of 1,3,5-trisubstituted barbiturates and thiobarbiturates were prepared in moderate to excellent yields and their activity as xanthine oxidase inhibitors, antioxidants, antibacterial agents and as anti-proliferative compounds was evaluated in vitro. Interesting bioactive barbiturates were found namely, 1,3-dimethyl-5-[1-(2-phenylhydrazinyl)ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione (6c) and 1,3-dimethyl-5-[1-[2-(4-nitrophenyl)hydrazinyl]ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione (6e), which showed concomitant xanthine oxidase inhibitory effect (IC50 values of 24.3 and 27.9 µM, respectively), and 2,2-diphenyl-1picrylhydrazyl (DPPH) radical scavenging activity (IC50 values of 18.8 and 23.8 µM, respectively). In addition, 5-[1-
Introduction
Barbituric acid (BA) is a relevant pyrimidine derivative that was synthesized for the first time in 1864 by cyclization of urea and malonic acid [1] . Until the commercialization of benzodiazepines in the 1960s, barbiturates were almost the only group of drugs used as sedative-hypnotics [2, 3] . More recently, this class of compounds has become increasingly attractive to medicinal chemists due to the discovery that they bear a wide range of biological activities. More specifically, several of these compounds are enzyme inhibitors [collagenase-3, matrix metalloproteinases (MMPs) [4] , xanthine oxidase (XO) [5] and methionine aminopeptidase-1] as well as antibacterial, anticancer, antiangiogenic, immunomodulatory, antifungal and antioxidant agents [6] [7] [8] [9] . These activities are associated to several structural changes at positions N1, N3, C2 and C5, the latter being the most studied position. Within these structural modifications, various cyclization reactions at C5 and C6 of BA, thiobarbituric acid (TBA) and their derivatives (BADs and TBADs, respectively) [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] as well as at C5 with spiro formation [20] [21] [22] [23] [24] have been described. Interestingly, some of these transformations involve a multicomponent reaction (MCR) [11, 14, 16] . However, in most cases, the cyclization path is preceded by the formation of substituted methyl [10, 18] , arylidene [12, 15, [19] [20] [21] [22] [23] [24] , or methylene [13, 17, 19] derivatives at C5 as key isolated or potential precursors of these modified pyrimidines. 6 From this set of compounds and to the best of our knowledge, two 5-phenylcyanomethylpyrimidines (4a-b), one 5-hydrazinylethylidenepyrimidine (6a), seven 5-phenylaminomethylenepyrimidines (7a-g) and six 1-(pyrimidine-5-ylidene)ureas and thioureas (8a-c, e-g) are described for the first time. All starting materials were commercially obtained, except 1,3-diphenylthiobarbituric acid (1a) which was synthesized from phenylisothiocyanate, aniline, malonic acid and acetyl chloride, in two steps [35, 36] . Almost all prepared 5substituted BADs and TBADs were easily isolated in a high degree of purity by simple filtration, as confirmed by nuclear magnetic resonance (NMR) spectra. In general, the BADs yields were higher than their congener TBADs.
Scheme 1. Chemical synthesis of BADs and TBADs 2-8.
A full spectroscopic characterization of all 5-substituted BADs and TBADs 2-8 was made, including 1 Hand 13 C-NMR shift assignments, which were established whenever possible with the aid of distortionless enhancement by polarization transfer (DEPT), heteronuclear multiple quantum coherence (HMQC) and heteronuclear multiple bond correlation (HMBC) experiments. The most representative 1 H-and 13 C-NMR chemical shifts of 5-substituted BADs and TBADs 2-8 are presented in Tables S2 and S3 , corresponding to the structural moiety depicted in bold, in Scheme 1.
5-Benzylidenepyrimidines 2a-e were synthesised by a Knoevenagel condensation reaction in excellent yields (90-97%), based on the method reported by Deb et al. [37] in which the reaction temperature was changed from 70 C to reflux. Then, the C-5 double bond of 5-benzylidenepyrimidine 2e was reduced at room temperature by NaBH4 in ethanol according to the method described by Yan et al. [38] to give compound 3, in 41% yield. The change of the yellow arylidene color to white, due to a conjugation extension reduction, together with the absence of the 1 H-NMR singlet at 8.25 ppm (2e unsaturated methine CH) and the observation of a triplet and doublet signals corresponding to the methine and methylene in adjacent carbons at 3.82 and 3.19 ppm, respectively, observed in the 1 H-NMR spectra of 3, are the most important evidences of a successful reduction reaction. Additionally, the cyanomethyl derivatives 4a-b were obtained, in 67-77% yield, from the respective 5-(4-bromobenzylidene)pyrimidines followed by the addition of sodium cyanide [39] .
Once again the reduction was evidenced by the change in color of the solid to white and by observation of deshielded methylene CH 1 H-NMR singlet signals at 5.24-5.35 ppm for compounds 4a-b.
The 5-acetylpyrimidines 5a-c were synthetized using the process described by Jursic et al. [40] in good to very good yields (45-83%) . Then, their hydrazine derivatives 6a-g were easily prepared after reaction with hydrazine and different phenylhydrazines, in refluxing methanol, using the method described by the same authors [40] , also in good to very good yields (50-92%).
The 5-phenylaminomethylenepyrimidines 7a-j and 1-(pyrimidin-5-ylidene)ureas/thioureas 8a-g were obtained in moderate to very good yields (52-98%) by reaction of triethyl orthoformate with urea or thiourea and different anilines, respectively, in refluxing butan-1-ol, by a MCR based on the method described by Rauf et al. [27] . In this procedure, the solvent was exchanged from butan-2-ol to butan-1-ol, which allowed the increase of the reflux temperature, resulting in higher yields of products. As representative examples, the yields of 5-phenylaminomethylenepyrimidines 7h and 7j were changed from 82 and 72% to 97 and 84%, respectively, when the reaction temperature increased.
Detailed 1 H-and 13 C-NMR analysis suggested that the enamine tautomer form A was present in all pyrimidine derivatives 6-8, in DMSO-d6. The imine form (hydrazone) B appears to be absent (Figure 1) , contrary to what was reported for 5-hydrazinylethylidenepyrimidines [28] . Specifically, the NH 1 H-NMR signal between 11.10 and 13.57 ppm correlated to the 5-C signal in HMBC experiments, which makes unequivocal evidence of the exclusive existence of tautomer A in DMSO-d6. 
Xanthine oxidase inhibitory activity
The evaluation of the XO inhibitory activity of BADs and TBADs 2-8 was made using a spectrophotometric method, under aerobic conditions, with xanthine as the substrate, and following uric acid formation by measuring the absorbance at 295 nm, as described in the literature [41, 42] . The commercial drug allopurinol was used as the positive control. The study started with a screening at 30 µM concentration (Table S4 ) and after this preliminary evaluation, concentration-response studies were performed for the BADs and TBADs which presented an inhibitory effect of 40% or higher, in order to determine their half maximal inhibitory concentration (IC50) values.
In general, the majority of BADs and TBADs was able to inhibit XO activity (Table S4) , with the most active compounds being the 5-benzylidenepyrimidines 2c and 2d and the 5-hydrazinylethylidenepyrimidines 6c and 6e ( Figure 2) , with an IC50 of 26.1, 31.5, 24.3 and 27.9 µM, respectively ( Table 1) . For the positive control (allopurinol) and under the assay conditions employed, an IC50 value of 3.17 µM was calculated, which is in agreement with the reported values [43] . Through the analysis of all these results, some important structural features for the XO inhibition could be inferred. Generally, BADs showed better XO inhibitory effect in comparison to their congeners TBADs, and bulkier substituents at C5 and smaller groups at N1 and N3 (Scheme 1) also seemed to favour this activity. Moreover, the 5-hydrazinylethylidenepyrimidine 6c, substituted with a methyl group at N1 and N3, clearly presented better activity than its hydrogenated analogue 6d. Additionally, the presence of a 2,4-dinitro system (6f) seemed to reduce this activity when compared to the congeners 5-hydrazinylphenyl 6c and 4-nitrophenyl 6e (Figure 2 ). as average values ± standard error of the mean (SEM). A p < 0.05 versus negative control in the statistical significance analysis (Student´s t-test) was observed for all compounds except for 6d. 
Antioxidant activity as DPPH radical scaveng er
The DPPH radical scavenging activity of BADs and TBADs 2-8 was evaluated using a spectrophotometric method by measuring the absorbance of this radical at 517 nm, based on the available literature [41, 42] and using Trolox as the reference compound. A screening was first performed at the concentration of 30 µM, after 20 and 60 minutes of incubation (Table S4) . IC50 values were further determined for BADs and TBADs which presented a DPPH radical scavenging activity higher than 50% ( Table 1 ).
Most of the tested compounds presented no appreciable DPPH radical scavenging capacity (Table S4) .
However, 5-hydrazinylethylidenepyrimidines 6c-e were clear exceptions ( Figure 3 ) and the determined IC50 values were 22.6, 23.9 and 23.9 µM, respectively, at 20 minutes, and 18.8, 20.4 and 23.8 µM, at 60 minutes 12 antioxidant action of other different organic hydrazines has already been described [45] [46] [47] . Finally, the 1-(pyrimidin-5-ylidene)ureas 8d and 8f exhibited a moderate radical scavenging activity ( Figure 3 ). Taken together, it is important to note the relevant XO inhibition and the high DPPH radical scavenging activity of the 5-hydrazinylethylidenepyrimidines 6c and 6e. As the new XO inhibitors should have a remarkable radical scavenging capacity, these results seem promising [43] .
Antibacterial activity 13
The antibacterial potential of all synthesized BADs and TBADs 2-8 was studied in Bacillus cereus, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella enterica subsp. enterica serovar Typhimurium and Acinetobacter baumannii strains, using tetracycline as the reference compound (Table S5) .
Regarding the antibacterial activity of the compounds under study, most of the assayed BADs and TBADs did not show activity against the tested Gram-positive and Gram-negative bacterial strains, with minimum inhibitory concentrations (MIC) higher than 200 µM. These results are in agreement with the previous reports referring to several 5-functionalized BADs and TBADs which were inactive against different strains of bacteria and fungi [28, [48] [49] [50] . However, pyrimidines 6c-d (MIC 25.0 µM) and 6e (MIC 12.5 µM) exhibited a relevant and selective antibacterial activity against A. baumannii. In fact, the presence of a p-nitrophenyl moiety bound to the hydrazine group of 5-hydrazinylethylidenepyrimidines (Scheme 1) seems to play an important role, since an increase in this antibacterial activity was observed in relation to the unsubstituted phenyl analogs 6c-d. In addition, the presence of more than one nitro group in the phenyl group (2,4- dinitrophenyl derivatives 6f-g) decreased the activity of these 5-hydrazinylethylidenepyrimidines. Hence, a suitable aromatic substituent at R3 of these pyrimidines can favour this activity. Furthermore, it is important to note that compound 6d, with unsubstituted pyrimidinone nitrogens, had antibacterial activity against A.
baumannii but was devoid of XO inhibitory effects.
The emergence of infections and outbreaks associated with strains of A. baumannii resistant to antibiotics, or even extensively drug-resistant and pandrug-resistant, has highlighted the lack of available drugs to treat infections by this bacterium. In fact, carbapenem-resistant A. baumannii is marked as one of the critical pathogens in the World Health Organization priority list for research and development of new antibiotics [51] .
Therefore, the activity of compounds 6c-e against A. baumannii makes them promising new starting points for the development of antibacterial agents against this high-profile pathogen.
Cytotoxicity studies in human cells
Considering the relevant results observed in the XO inhibition, DPPH radical scavenging and antibacterial studies, the cytotoxicity of BADs and TBADs 2-8 was evaluated in normal human dermal fibroblasts (NHDF). Additionally, a mammalian breast cancer cell line (MCF-7) was included in this study to evaluate the anti-proliferative potential and selectivity of these compounds. The well-established 3-(4,5dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay [52] was used in which the soluble yellow MTT is converted into purple and insoluble formazan crystals by active mitochondrial lactate dehydrogenases of living cells [53] . Initially, both cell lines were exposed to BADs and TBADs 2-8 at the concentration of 30 µM, during a period of 72 h. Untreated cells were used as the negative control and cells treated with 5-fluorouracil (5-FU) as the positive control.
The results (Table S4 ) showed that most of the compounds were not markedly cytotoxic for NHDF cells at 30 µM. Additionally, the IC50 of 5-hydrazinylethylidenepyrimidine 6c was determined as a representative example of pyrimidines 6c-e, and a value of 82.0 µM was obtained. Considering the potential future use of this type of compounds in the treatment of A. baumannii infections, this can be an interesting result as it demonstrates a possible selectivity of these agents for bacterial versus normal human cells.
On the other hand, a more marked reduction of MCF-7 cells proliferation was observed ( Figure 4 and Table   S4 ). The phenylaminomethylpyrimidines 7 seemed to have higher cytotoxicity than the other groups of compounds. Specifically, it is clear that the 5-hydrazinylethylidenepyrimidine 6d and the 5phenylaminomethylenepyrimidines 7d-e,g-h have a relevant anti-proliferative effect at 30 µM. In this last group, the presence of a chloro or a carboxyl group at position 2 of the aromatic ring (Scheme 1) seems to improve this activity when compared to the compound containing the nitro (7f) group in the same position.
For the 5-phenylaminomethylenepyrimidine 7d, the most cytotoxic compound in MCF-7 cells at 30 µM, the IC50 value was 13.3 µM. Considering its selectivity for cancer cells versus NHDFs, this structure can be a future starting point to develop this class of compounds as potential novel anticancer agents. 
In Silico studies
Poor pharmacokinetics and/or unacceptable side effects are the main reasons why the majority of drugs evaluated in clinical trials do not reach the market [54] . Thus, computational approaches to predict the absorption, distribution, metabolism, excretion and toxicity (ADMET) may be a decisive tool to minimize these risks. The PkCSM online software (available from http://bleoberis.bioc.cam.ac.uk/pkcsm/prediction) is a recent freely accessible web platform that allows rapid evaluation of pharmacokinetic and toxicity properties and was herein used for the in silico evaluation of the drug-likeness, in terms of the Lipinski's rule of five (Table S6) , and to predict ADMET properties (Table S7) for the six most promising pyrimidines (2c,d, 6c-e and 7d) tested in vitro.
Four parameters are taken into consideration in the Lipinski's rule of five, including an n-octanol-water partition coefficient (log P) no higher than 5, a molecular weight (MW) lower than 500 Da, no more than 10 hydrogen bond acceptors (n-HBA) and no more than 5 hydrogen bond donors (n-HBD) [54] . Generally, an orally active drug has no more than one violation [55] . According to Table S6 , all these pyrimidines are compatible with the parameters of the Lipinski's rule of five, suggesting that these compounds have favourable properties to accomplish the drug-likeness criteria.
The pkCSM online software was also used to predict pharmacokinetic and toxicity properties of pyrimidines 2c-d, 6c-e and 7d (Table S7 ). The pyrimidines 2c,d, 6c-e and 7d entirely fulfil the Lipinski's rule of five and a good intestinal absorption was predicted. However, for compounds 2d and 6d-e a poor Caco-2 permeability was estimated. In addition, despite the fact that pyrimidines 6e and 7d can be potential Pglycoprotein substrates, it was predicted that all studied compounds should not be potential P-glycoprotein I/II inhibitors. Therefore, a low probability of pharmacokinetic interactions involving this protein is expected. A similar situation should occur in the case of the excretory protein organic cation transporter 2 (OCT2). In the distribution field, a generic tendency for a low probability for these compounds to access the central nervous system was estimated. Concerning metabolism, in which the cytochrome P450 isoforms have a key role, only the 5-phenylaminomethylenepyrimidine 7d was predicted to be a potential substrate of the important isoform CYP3A4. In general, it is expected that pyrimidines 2c,d, 6c-e and 7d should accomplish most of the pharmacokinetic and toxicity criteria studied, however, the estimated maximum tolerated dose in humans and potential genotoxicity (Ames toxicity) for several compounds (Table S7 ) appeared to be the potential major problems. In fact, a mutagenic potential for the nitroaromatic derivatives 2c-d, 6e and 7d is expected and therefore this point should be experimentally studied and the use of non-mutagenic bioisosteres should be considered.
Conclusion
A series of 1,3-trisubstituted barbiturates and thiobarbiturates substituted at the position 5 with benzylidene, benzyl, phenylcyanomethyl, acetyl, hydrazinylethylidene, phenylhydrazinylethylidene, phenylaminomethylene ylideneureas and the corresponding thioureas were synthesized, in moderate to excellent yields. In addition, the activity of these compounds as xanthine oxidase inhibitors, antioxidants as well as antibacterial and anti-proliferative agents was also evaluated. Some of the synthesized barbiturates were found to have potential for health-related applications, namely 1,3-dimethyl- fulfil the Lipinski's rule of five as well as most of the pharmacokinetic and toxicity criteria determined for the different ADMET parameters. Therefore, a novel compound class with members bearing xanthine oxidase inhibitory activity, antioxidant effects as well as anti-proliferative action and the ability to inhibit the growth of Acinetobacter baumannii was revealed. However, future studies should be performed to improve not only the potency and selectivity of this family of compounds but also its pharmacokinetics.
Experimental section

Chemistry
All reagents were purchased from commercial suppliers and used without further purification. [37] . A stirred mixture of compound 1a-d (1.00 mmol) and benzaldehyde (1.00 mmol) in water (5 mL) was refluxed for 2 hours. After cooling, the formed product was filtered, washed with water, ethanol and diethyl ether to give the following 5-benzylidenepyrimidines: [39] . A stirred suspension of compound 1b-c (1.00 mmol) and 4-bromobenzaldehyde (1.00 mmol) in water (5 mL) was refluxed for 2 hours. After cooling, sodium cyanide (1.00 mmol) was added and the resulting mixture was stirred at 70 °C. The reaction was followed by TLC (dichloromethane/methanol 20%) and completed after 1 hour. The reaction mixture was evaporated to dryness and the obtained solid was dissolved in an equimixture of methanol and ethyl acetate. The product formed after partial evaporation of the solvent was filtered and washed with diethyl ether to give the following 5-phenylcyanomethylpyrimidines: 4.1.6. 5-Acetylpyrimidines (5a-c) [40] . A solution of compound 1a or 1c-d (1.00 mmol) and concentrated sulfuric acid (0.100 mmol) was refluxed in acetic anhydride (1.00 mmol) for 1 hour. The reaction was followed by TLC (dichloromethane/5% methanol). The reaction mixture was concentrated to half of the initial volume and poured onto ice. The formed solid was isolated, washed with hot water, dried and recrystallized from ethanol/water (2:1) to give the following 5-acetylpyrimidines: 6.1. 5-Acetyl-1,3-diphenyl-2-thioxodihydropyrimidine-4,6(1H,5H) [40] . A stirred suspension of 5-acetylpyrimidine 5a-c (1.00 mmol) and the appropriate hydrazine (1.00 mmol) in methanol (20 mL) was refluxed overnight. The formed solid was filtrated, washed with hot water and methanol to give the following 5hydrazinylethylidenepyrimidines:
5-(1-Hydrazinylethylidene)-1,3-diphenyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (6a).
From 5-Phenylaminomethylenepyrimidines (7a-j) . Obtained from the corresponding compounds 1a-c and anilines by the reaction conditions A or B adapted from the literature [27] . All products were isolated by hot filtration and washed with hot ethanol and diethyl ether to give the following 5phenylaminomethylenepyrimidines.
Reaction conditions A:
A stirred mixture of compound 1b-c (1.00 mmol) and triethyl orthoformate (1.00 mmol) was refluxed in butan-1-ol (10 mL). o-Phenylenediamine (1.00 mmol) was added after approximately 1 hour, when the color of the reaction mixture changed to red. The resulting mixture was refluxed for 3 hours.
Reaction conditions B:
A stirred mixture of compound 1a-d (1.00 mmol), appropriate aniline (1.00 mmol) and triethyl orthoformate (1 mL) was refluxed in butan-1-ol (10 mL) for 4 hours. 4. 1.8.9. 2-[[(1,3-Dimethyl-2,4,6-trioxotetrahydropyrimidin-5(2H) sub-cultured on Müeller Hinton Agar and incubated overnight at 37 ºC prior to each antimicrobial assay.
5-[[(2-Aminophenyl)amino]methylene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (7a
Determination of mini mum inhibitory concentration (MIC)
The antibacterial activity of the test compounds was studied by measurement of MIC by broth microdilution forming units/ml, and the plate was incubated at 37 ºC for 24 h. Sterility, solvent and growth controls were included in the assays, also tetracycline was used as reference. The MIC was defined as the lowest concentration at which no growth was visually observed. Each test was carried out at least three independent times and modal MIC values were selected.
Cytotoxicity in human cell lines
Preparation of sample solutions
All the tested compounds were dissolved in DMSO in a concentration of 10 mM and stored at 4 °C. From this solution, several solutions of the compounds in study were prepared by their adequate dilutions in the complete culture medium before each experiment. The maximum DMSO concentration in the studies was 1%
(v/v), a concentration with no significant effect on cell proliferation (data not shown).
Cells cultures
The cells used in this study were human breast cancer cells (MCF-7) and normal human dermal fibroblasts (NHDF) and were obtained from American Type Culture Collection (ATCC). These cells were maintained at 37 ºC in a humidified atmosphere containing 5% CO2. MCF-7 cells were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic/antimycotic (10,000 units/mL penicillin, 10 mg/mL streptomycin and 25 µg/mL amphotericin B).
The RPMI medium supplemented with 10% fetal bovine serum (FBS), L-glutamine (2 mM), HEPES (10 mM), sodium pyruvate (1 mM) and 1% antibiotic/antimycotic was used to culture NHDF cells. The cells used in the experiments were used in passages 26 to 31 (MCF-7) and 6 to 11 (NHDF).
MTT assay
The cell proliferation was evaluated by quantifying the extent of the reduction of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) according to a previously described procedure [52] . Cells were seeded in 96-well plates (2×10 4 cells/mL) in the culture medium and after 48 h of adherence they were treated with the different compounds and concentrations under study for 72 h. Untreated cells were used as negative control and 5-FU as positive control. At the end of incubation, the medium was removed and replaced with fresh culture medium and MTT solution [5 mg/mL in phosphate buffer saline (NaCl 137 mM, KCl 2.7 mM, Na2HPO4 10 mM and KH2PO4 1.8 mM), pH 7.4] and further incubated at 37 C during 4 h. Then, the medium-containing MTT was removed and formazan crystals were dissolved with DMSO followed by absorbance readings at 570 nm. The cytotoxicity was expressed as the relative cell proliferation in percentage in comparison with the negative control cells.
Statistics
The results are expressed as mean values ± standard error of the mean (SEM) and are representative of least two independent experiments. The difference between groups was considered statistically significant at p<0.05 (Student´s t-test) . The IC50 values were calculated by sigmoidal fitting analysis considering a 95% confidence interval.
In silico simulations
The structures of tested compounds were manually drawn in ChemBioDraw 13.0 software and the SMILES notation was obtained for each molecule. To calculate the parameters of Lipinski's rule of five, pharmacokinetic (absorption, distribution, metabolism and excretion) and toxicity properties, the SMILES notation in PkCSM online software (available from http://bleoberis.bioc.cam.ac.uk/pkcsm/prediction, accessed at 04.04.17) was employed [54] . 
Figure Captions
